BEAM THERAPEUTICS INC. - COMMON STOCK

Beam Therapeutics to Participate in Upcoming September Investor Conferences

31 Aug 2023 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results

08 Aug 2023 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in Upcoming May Investor Conferences

17 May 2023 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference

11 May 2023 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results

10 May 2023 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day

27 Mar 2023 07:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer

21 Mar 2023 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference

15 Mar 2023 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the 43rd Annual Cowen Healthcare Conference

01 Mar 2023 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones

28 Feb 2023 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference

07 Feb 2023 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones

09 Jan 2023 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

03 Jan 2023 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead of Autologous Transplant

10 Dec 2022 10:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022

02 Dec 2022 14:00:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201

02 Dec 2022 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference

30 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease

14 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics to Participate in Upcoming Investor Conferences

09 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results

07 Nov 2022 06:30:00 By Nasdaq GlobeNewswire